𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody

✍ Scribed by Cristoph Renner; Frank Hartmann; M. Pfreundschuh

Publisher
Springer-Verlag
Year
1997
Tongue
English
Weight
164 KB
Volume
45
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A CD16/CD30 bispecific monoclonal antibo
A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo
✍ Andreas Hombach; Wolfram Jung; Christoph Pohl; Christoph Renner; Ugur Sahin; Rud 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 808 KB

In order to target NK cells against the Hodgkin's-derived cell line L540, we developed bispecific monoclonal antibodies (Bi-MAbs) by somatic hybridization of the 2 mouse hybridoma cell lines HRS-3 and A9 which produce monoclonal antibodies (MAbs) with reactivity against the Hodgkin and Reed-Sternber

Treatment of B-cell non-Hodgkin's lympho
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have